{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:46:21Z","timestamp":1755218781304,"version":"3.43.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.canrad.2025.104665","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T05:26:12Z","timestamp":1750742772000},"page":"104665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prise en charge de la gyn\u00e9comastie \u00e0 l\u2019\u00e8re des inhibiteurs des r\u00e9cepteurs aux androg\u00e8nes chez les patients atteints de cancer de la prostate"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8516-110X","authenticated-orcid":false,"given":"Nassim","family":"Vibert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9rane","family":"Achard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Pouvreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Huck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2025.104665_bib0290","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.euo.2024.01.009","article-title":"A phase 2\u00a0randomized open-label study of oral darolutamide monotherapy versus androgen deprivation therapy in men with hormone-sensitive prostate cancer (EORTC-GUCG 1532)","volume":"7","author":"Tombal","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.canrad.2025.104665_bib0295","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104665_bib0300","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1200\/JCO.22.01662","article-title":"Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: the SALV-ENZA trial","volume":"41","author":"Tran","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104665_bib0305","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104665_bib0310","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104665_bib0315","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3\u00a0trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104665_bib0320","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104665_bib0325","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJMcp070677","article-title":"Gynecomastia","volume":"357","author":"Braunstein","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104665_bib0330","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2004.03.022","article-title":"Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia","volume":"60","author":"Tyrrell","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104665_bib0335","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","article-title":"EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent\u00a0\u2014\u00a0update 2013","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104665_bib0340","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00266-008-9213-z","article-title":"Quality of life in the surgical treatment of gynecomastia","volume":"33","author":"Davan\u00e7o","year":"2009","journal-title":"Aesth Plast Surg"},{"key":"10.1016\/j.canrad.2025.104665_bib0345","first-page":"CD009266","article-title":"Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer","volume":"2014","author":"Kunath","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.canrad.2025.104665_bib0350","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.euros.2025.01.001","article-title":"Incidence, management, and prevention of gynecomastia and breast pain in patients with prostate cancer undergoing antiandrogen therapy: a systematic review and meta-analysis of randomized controlled trials","volume":"73","author":"Tsuboi","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.canrad.2025.104665_bib0355","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.clgc.2013.05.004","article-title":"Luteinizing hormone-releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects","volume":"11","author":"Walker","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.canrad.2025.104665_bib0360","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/annonc\/mdr447","article-title":"Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy","volume":"23","author":"Storey","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104665_bib0365","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O\u2019Farrell","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104665_bib0370","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020\u00a0update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"year":"2023","series-title":"FDA approves enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrence","key":"10.1016\/j.canrad.2025.104665_bib0375"},{"key":"10.1016\/j.canrad.2025.104665_bib0380","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2025.02.006","article-title":"Effects of enzalutamide on the sexual activity of patients with biochemically recurrent prostate cancer: a post hoc analysis of patient-reported outcomes in the EMBARK study","volume":"87","author":"Freedland","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104665_bib0385","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00066-020-01598-9","article-title":"Treatment strategies to prevent and reduce gynecomastia and\/or breast pain caused by antiandrogen therapy for prostate cancer: statement from the DEGRO working group prostate cancer","volume":"196","author":"Ghadjar","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2025.104665_bib0390","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020\u00a0update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104665_bib0395","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1590\/S1516-31802012000300009","article-title":"Gynecomastia: physiopathology, evaluation and treatment","volume":"130","author":"Barros","year":"2012","journal-title":"Sao Paulo Med J"},{"key":"10.1016\/j.canrad.2025.104665_bib0400","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamaoncol.2022.1641","article-title":"Enzalutamide monotherapy vs active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial","volume":"8","author":"Shore","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2025.104665_bib0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/5454727","article-title":"Randomized, open-label phase 2\u00a0study of apalutamide plus androgen deprivation therapy versus apalutamide monotherapy versus androgen deprivation monotherapy in patients with biochemically recurrent prostate cancer","volume":"2022","author":"Aggarwal","year":"2022","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.canrad.2025.104665_bib0410","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2021.08.032","article-title":"A phase 2\u00a0randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)","volume":"158","author":"Maluf","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2025.104665_bib0415","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0090-4295(96)80006-9","article-title":"Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial","volume":"47","author":"Soloway","year":"1996","journal-title":"Urology"},{"year":"2017","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version\u00a05","key":"10.1016\/j.canrad.2025.104665_bib0420"},{"key":"10.1016\/j.canrad.2025.104665_bib0425","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1016\/j.jacr.2018.09.017","article-title":"ACR Appropriateness Criteria\u00ae evaluation of the symptomatic male breast","volume":"15","author":"Niell","year":"2018","journal-title":"J Am Coll Radiol"},{"key":"10.1016\/j.canrad.2025.104665_bib0430","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0025-6196(11)60671-X","article-title":"Gynecomastia: pathophysiology, evaluation, and management","volume":"84","author":"Johnson","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.canrad.2025.104665_bib0435","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00006534-197301000-00009","article-title":"Classification and surgical correction of gynecomastia","volume":"51","author":"Simon","year":"1973","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.canrad.2025.104665_bib0440","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.juro.2010.03.137","article-title":"Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and\/or breast pain?","volume":"184","author":"Ozen","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2025.104665_bib0445","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0090-4295(02)02107-6","article-title":"Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253\u00a0patients in the randomized Scandinavian trial SPCG-7\/SFUO-3","volume":"61","author":"Widmark","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.canrad.2025.104665_bib0450","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2009.05.019","article-title":"An open, randomised, multicentre, phase 3\u00a0trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients","volume":"57","author":"Bedognetti","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104665_bib0455","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.2005.12.013","article-title":"Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer","volume":"23","author":"Boccardo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104665_bib0460","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2007.01.031","article-title":"Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose\u2013response study","volume":"52","author":"Fradet","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104665_bib0465","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.pcan.4500782","article-title":"Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole","volume":"8","author":"Saltzstein","year":"2005","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.canrad.2025.104665_bib0470","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clgc.2012.03.002","article-title":"A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia","volume":"10","author":"Serretta","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.canrad.2025.104665_bib0475","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1097\/01.ju.0000181824.28382.5c","article-title":"Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy","volume":"174","author":"Di Lorenzo","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2025.104665_bib0480","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(05)70103-0","article-title":"Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial","volume":"6","author":"Perdon\u00e0","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104665_bib0485","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0007-1226(03)00111-5","article-title":"A systematic approach to the surgical treatment of gynaecomastia","volume":"56","author":"Fruhstorfer","year":"2003","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.canrad.2025.104665_bib0490","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3747\/co.19.993","article-title":"Optimal prophylactic and definitive therapy for bicalutamide-induced gynecomastia: results of a meta-analysis","volume":"19","author":"Tunio","year":"2012","journal-title":"Cur Oncol"},{"key":"10.1016\/j.canrad.2025.104665_bib0495","doi-asserted-by":"crossref","first-page":"e3161","DOI":"10.1097\/GOX.0000000000003161","article-title":"Surgical management of gynecomastia: a comprehensive review of the literature","volume":"8","author":"Holzmer","year":"2020","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"10.1016\/j.canrad.2025.104665_bib0500","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/annonc\/mdr459","article-title":"Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects","volume":"23","author":"Pemmaraju","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104665_bib0505","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/andr.12197","article-title":"Tamoxifen in men: a review of adverse events","volume":"4","author":"Wibowo","year":"2016","journal-title":"Andrology"},{"key":"10.1016\/j.canrad.2025.104665_bib0510","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41416-018-0369-2","article-title":"Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis","volume":"120","author":"Eggemann","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2025.104665_bib0515","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1470-2045(08)70077-9","article-title":"The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial","volume":"9","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104665_bib0520","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijrobp.2018.01.096","article-title":"Does prophylactic radiation therapy to avoid gynecomastia in patients with prostate cancer increase the risk of breast cancer?","volume":"101","author":"Aksness\u00e6ther","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104665_bib0525","first-page":"239269","article-title":"Prophylactic breast bud radiotherapy for patients taking bicalutamide: should this still be practised for patients with prostate cancer?","volume":"2012","author":"Lewis","year":"2012","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.canrad.2025.104665_bib0530","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.radonc.2014.10.004","article-title":"Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468\u00a0patients","volume":"114","author":"Grantzau","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104665_bib0535","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.bjc.6605435","article-title":"Second solid cancers after radiotherapy for breast cancer in SEER cancer registries","volume":"102","author":"Berrington De Gonzalez","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2025.104665_bib0540","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1016\/j.ijrobp.2012.01.036","article-title":"Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy?","volume":"83","author":"Viani","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104665_bib0545","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.eururo.2004.12.003","article-title":"Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer","volume":"47","author":"Van Poppel","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104665_bib0550","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00066-011-2283-x","article-title":"Radiotherapy for prevention and therapy of gynecomastia due to antiandrogen treatment in prostate cancer patients: a patterns-of-care study","volume":"187","author":"Neu","year":"2011","journal-title":"Strahlenther Onkol"},{"year":"2017","series-title":"Xtandi, INN-enzalutamide. R\u00e9sum\u00e9 des caract\u00e9ristiques du produit","key":"10.1016\/j.canrad.2025.104665_bib0555"},{"year":"2019","series-title":"Erleada, INN-apalutamide. R\u00e9sum\u00e9 des caract\u00e9ristiques du produit","key":"10.1016\/j.canrad.2025.104665_bib0560"},{"year":"2020","series-title":"Nubeqa, INN-darolutamide. R\u00e9sum\u00e9 des caract\u00e9ristiques du produit","key":"10.1016\/j.canrad.2025.104665_bib0565"},{"key":"10.1016\/j.canrad.2025.104665_bib0570","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ctrv.2015.01.002","article-title":"Individualization of tamoxifen therapy: much more than just CYP2D6\u00a0genotyping","volume":"41","author":"Binkhorst","year":"2015","journal-title":"Cancer Treat Rev"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825000812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825000812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T11:47:57Z","timestamp":1754480877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825000812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1278321825000812"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104665","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge de la gyn\u00e9comastie \u00e0 l\u2019\u00e8re des inhibiteurs des r\u00e9cepteurs aux androg\u00e8nes chez les patients atteints de cancer de la prostate","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO).","name":"copyright","label":"Copyright"}],"article-number":"104665"}}